In This Article:
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Picking the right S&P 500 stocks requires more than just buying big names, and that’s where StockStory comes in. That said, here are three S&P 500 stocks that don’t make the cut and some better choices instead.
Lamb Weston (LW)
Market Cap: $7.17 billion
Best known for its Grown in Idaho brand, Lamb Weston (NYSE:LW) produces and distributes potato products such as frozen french fries and mashed potatoes.
Why Does LW Give Us Pause?
-
Projected sales are flat for the next 12 months, implying demand will slow from its three-year trend
-
Efficiency has decreased over the last year as its operating margin fell by 5 percentage points
-
Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
Lamb Weston’s stock price of $50.60 implies a valuation ratio of 14.8x forward P/E. If you’re considering LW for your portfolio, see our FREE research report to learn more.
Verizon (VZ)
Market Cap: $185.1 billion
Formed in 1984 as Bell Atlantic after the breakup of Bell System into seven companies, Verizon (NYSE:VZ) is a telecom giant providing a range of communications and internet services.
Why Should You Sell VZ?
-
Weak customer trends over the past two years suggest it may need to improve its products, pricing, or go-to-market strategy
-
Capital intensity will likely increase as its free cash flow margin is anticipated to drop by 2.2 percentage points over the next year
-
Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
At $43.93 per share, Verizon trades at 9.3x forward P/E. To fully understand why you should be careful with VZ, check out our full research report (it’s free).
Thermo Fisher (TMO)
Market Cap: $154 billion
With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide.
Why Are We Wary of TMO?
-
Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
-
Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 10 percentage points
-
Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability